Where does Helen Kim work?

Helen Kim is Senior Managing Director at Vida Ventures and Board director at Exicure and Board director at Protego Biopharma.

What check size does Helen Kim write?

Helen Kim typically writes checks of $100K – $10M.

Where did Helen Kim go to school?

Helen Kim studied at The University of Chicago Booth School of Business (MBA); Northwestern University (BS, Chemical Engineering).

Helen Kim

Investor

Senior Managing Director at Vida Ventures · Board director at Exicure · Board director at Protego Biopharma

Santa Monica, California

Writes $100K – $10M checks · typically $1M

Find your path to Helen

265 people in our graph can introduce you to Helen.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Chris Weyrer to introduce you to Helen

You →Chris · together at Protego Biopharma (2024–2026) →Helen

Ask Jamie Chen to introduce you to Helen

You →Jamie · together at ReCode Therapeutics →Helen

Ask Sam Okafor to introduce you to Helen

You →Sam · 2 people · together at Exicure →Helen

Your email: the people you already email who know Helen
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Helen
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Helen Kim serves on the board of directors at Prothena Corporation plc and as a board member at Applied Molecular Transport. She has held executive management positions at NGM Biopharmaceuticals, Kosan, Affymax, Onyx, Protein Design Labs, and Chiron. Kim holds a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.

Board director at Exicure

Intro paths

→

In turn, Helen can intro founders to Exicure's investors below.

Exicure's investors · 4

AbbVieCambridge · $300K – $3M checks Innovation EndeavorsPalo Alto · $1M – $15M checks Purple Arch VenturesBoston RockPort Capital PartnersBoston

Co-founders at Exicure

Chad A. MirkinDirector

C. Shad ThaxtonDirector

David A. GiljohannChief Executive Officer

Board director at Protego Biopharma

Intro paths

→

In turn, Helen can intro founders to Protego Biopharma's investors below.

Protego Biopharma's investors · 8

Digitalis VenturesNew York · $100K – $10M checks · since 2025 Droia VenturesLuxembourg · $540K checks · since 2025 ForbionNaarden · since 2025 Lightspeed Venture PartnersMenlo Park · $1M – $5M checks · since 2025 MPM BioImpactBoston · $1M – $15M checks · since 2025 Novartis Venture FundBasel · $5M – $25M checks · since 2025 Vida VenturesLos Angeles · since 2025 YK BioventuresBurlingame · since 2025

Experience

Prothena Corporation plcMember Board of Directorscurrent2022 — present
InduProMember Board of Directorscurrent2022 — present
Protego BiopharmaMember Board of Directorscurrent2021 — present
Aktis OncologyMember Board of Directorscurrent2021 — present
IconOVir BioMember Board of Directorscurrent2020 — present
ReCode TherapeuticsMember Board of Directorscurrent2020 — present
Vida Ventures, LLCSenior Managing Directorcurrent2019 — presentSanta Monica, CA
A2 Biotherapeutics, Inc.Board Membercurrent2019 — present
Applied Molecular TransportBoard Member2018 — 2022South San Francisco
Assembly Biosciences, Inc.Member Board Of Directors2018 — 2020
ExicureBoard Member2014 — 2020Greater Chicago Area
The Column GroupPartner2018 — 2019San Francisco Bay Area
Kite Pharma, Inc.Executive Vice President2014 — 2018Santa Monica, CA
Forsight Vision 4Board Member2012 — 2017
Sunesis PharmaceuticalsBoard Director2009 — 2016
NGM Biopharmaceuticals, Inc.Strategic Advisor formerly Chief Business Officer2009 — 2014
ImmunoCellular Therapeutics LtdBoard member2011 — 2014Calabasas
West Coast Clinical Trials, GlobalBoard director2011 — 2012Costa Mesa, CA
Trinity BiosystemsBoard member2009 — 2010
Kosan BiosciencesPresident and CEO2007 — 2008
Gordon and Betty Moore FoundationChief Program Officer2003 — 2007
AffymaxChief Business Officer2002 — 2003
Onyx Pharmaceuticals Inc.Sr. Vice President, Corporate Development1999 — 2002
PDL PharmaVice President, Marketing and Product Development1998 — 1999
ChironVice President, Marketing & Business Development1989 — 1998

Colleagues at Vida Ventures

Alessandro Giacometti

Vice President, Head of Investor Relations at Vida Ventures

Alex Loftis

Principal at Vida Ventures

Alex Mejia

Executive Services Manager at Vida Ventures

Alex Shen

Director of Operations at Vida Ventures

Andy Kadlec

Senior Associate at Vida Ventures

Anita Keenan

Executive Assistant at Vida Ventures

Arie Belldegrun

Founder and Senior Managing Director at Vida Ventures

Arjun Goyal

General Partner at Vida Ventures

Network2

Carla Daniel

Partner at The Column Group

David V. Goeddel

Managing Partner at The Column Group

Investors connected to Helen in public investor directories — a warm-intro map.

Frequently asked questions

Who is Helen Kim?: Helen Kim serves on the board of directors at Prothena Corporation plc and as a board member at Applied Molecular Transport. She has held executive management positions at NGM Biopharmaceuticals, Kosan, Affymax, Onyx, Protein Design Labs, and Chiron. Kim holds a BS in Chemical Engineering from Northwestern University and an MBA from the University of Chicago.
Where does Helen Kim work?: Helen Kim is Senior Managing Director at Vida Ventures and Board director at Exicure and Board director at Protego Biopharma.
What check size does Helen Kim write?: Helen Kim typically writes checks of $100K – $10M.
Where did Helen Kim go to school?: Helen Kim studied at The University of Chicago Booth School of Business (MBA); Northwestern University (BS, Chemical Engineering).